Brown Advisory Inc. Purchases 1,909,118 Shares of Illumina, Inc. (NASDAQ:ILMN)

Brown Advisory Inc. raised its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 54,220.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,912,639 shares of the life sciences company's stock after purchasing an additional 1,909,118 shares during the quarter. Brown Advisory Inc. owned 1.21% of Illumina worth $255,586,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in ILMN. Bamco Inc. NY grew its position in Illumina by 6.3% during the fourth quarter. Bamco Inc. NY now owns 407,901 shares of the life sciences company's stock valued at $54,508,000 after buying an additional 24,280 shares during the period. Banque Transatlantique SA bought a new position in shares of Illumina during the 4th quarter valued at approximately $89,000. Bayesian Capital Management LP increased its stake in shares of Illumina by 87.5% during the 4th quarter. Bayesian Capital Management LP now owns 13,500 shares of the life sciences company's stock worth $1,804,000 after purchasing an additional 6,300 shares during the last quarter. Benjamin Edwards Inc. bought a new stake in shares of Illumina in the 4th quarter worth approximately $541,000. Finally, BNP Paribas purchased a new position in Illumina in the fourth quarter valued at approximately $302,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Price Performance

Shares of ILMN stock traded up $1.82 during trading hours on Wednesday, hitting $76.35. 2,467,306 shares of the company's stock were exchanged, compared to its average volume of 2,274,015. The company has a market capitalization of $12.08 billion, a PE ratio of -9.94, a PEG ratio of 1.60 and a beta of 1.35. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The business's 50 day simple moving average is $79.46 and its 200-day simple moving average is $114.71.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, equities research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analyst Weigh In

ILMN has been the topic of several research reports. Canaccord Genuity Group lowered their target price on Illumina from $115.00 to $92.00 and set a "hold" rating on the stock in a research note on Tuesday, April 29th. Piper Sandler boosted their price objective on Illumina from $185.00 to $190.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. Stephens reiterated an "overweight" rating and set a $156.00 target price on shares of Illumina in a research report on Tuesday, March 11th. HSBC lowered shares of Illumina from a "buy" rating to a "hold" rating and set a $100.00 price target on the stock. in a research report on Friday, February 28th. Finally, Morgan Stanley cut their price objective on shares of Illumina from $150.00 to $136.00 and set an "equal weight" rating for the company in a report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Illumina currently has an average rating of "Moderate Buy" and a consensus target price of $137.55.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.